New hope for hard-to-treat breast cancer: drug combo targets resistance
NCT ID NCT04090567
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tests whether adding another drug (cediranib or AZD6738) to the PARP inhibitor olaparib can shrink tumors or slow cancer growth in people with advanced BRCA-mutated breast cancer that has stopped responding to PARP inhibitors. About 60 adults with HER2-negative, BRCA-positive advanced breast cancer will receive one of the combinations. The goal is to find a way to overcome drug resistance and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.